trial

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

NCTId NCT02765555
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Indivior Inc.
Primary completion 2010-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-03
Primary completion
2010-09
Eligibility
ALL · 18 Years · 42 Years

Interventions & indications

Drugs
RBP-7000

Sponsors

Indivior Inc.Lead Sponsor

Sites

1 total
Willingboro, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2010-09
Status
COMPLETED
relationships
The graph out of here
drug
RBP-7000
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication